

Title (en)  
IODINATED FATTY ACID ESTERS CONTAINING A MINIMUM OF 50 PERCENT OF MONIODOSTEARIC ACID ESTERS OR DERIVATIVES IN THE FORM OF A SOFT CAPSULE OR A GEL CAPSULE, OF USE DURING A NUCLEAR ACCIDENT

Title (de)  
JODIERTE FETTSÄUREESTER MIT MINDESTENS 50 PROZENT ANTEIL AN MONOJODSTEARINSÄUREESTERN ODER DERIVATEN IN FORM EINER WEICHKAPSEL ODER GELKAPSEL, ZUR VERWENDUNG BEI EINEM REAKTORUNFALL

Title (fr)  
ESTERS D'ACIDES GRAS IODÉS CONTENANT AU MINIMUM 50 POUR CENT D'ESTERS D'ACIDE MONIODOSTÉARIQUE OU DÉRIVÉS SOUS FORME DE CAPSULE MOLLE OU DE GÉLULE, UTILES LORS D'UN ACCIDENT NUCLÉAIRE

Publication  
**EP 2720687 A1 20140423 (FR)**

Application  
**EP 12731520 A 20120608**

Priority  
• FR 1101814 A 20110614  
• FR 2012000231 W 20120608

Abstract (en)  
[origin: WO2012172192A1] Iodinated fatty acid esters containing a minimum of 50 percent of moniodostearic acid esters such as ethyl esters of fatty acids originating from rapeseed oil, or derivatives, of pharmaceutical purity, which are completely iodinated, no longer have double bonds, and are stable, for preparing an organism-protecting product, of medicament quality, either in the pure state in a pharmaceutical form such as a soft capsule or a gel capsule, or in combination with excipients in a soft-capsule or gel-capsule form, for oral administration, which is of use during a nuclear accident, enabling a prolonged provision of an additional dose of iodine to the thyroid gland and in which the amount of iodine administered follows the recommendations of the World Health Organization. Thus, the use of defined doses for oral administration, stable for 5 years or even 10 years at 25°C, either of a soft capsule containing 351 mg of Brassiodol corresponding to a concentration of 100 mg of 127I for children over the age of 12 and adults, or of a soft capsule containing 175 mg of Brassiodol corresponding to a concentration of 50 mg of 127I for children from 36 months to 12 years old, or of a soft capsule containing 88 mg of Brassiodol corresponding to a concentration of 25 mg of 127I for infants from 1 to 36 months old, is recommended. These soft capsules of Brassiodol can be used by populations in regions where there is a relative deficiency in dietary iodine, allowing supplementary preventive coverage for the thyroid gland for 6 months.

IPC 8 full level  
**A61K 9/48** (2006.01); **A61K 31/20** (2006.01); **A61K 31/23** (2006.01); **A61K 33/18** (2006.01)

CPC (source: EP)  
**A61K 9/4858** (2013.01); **A61K 9/4875** (2013.01); **A61K 31/20** (2013.01); **A61K 31/23** (2013.01); **A61K 33/18** (2013.01)

Citation (search report)  
See references of WO 2012172192A1

Citation (examination)  
J. WOLFF: "Physiology and Pharmacology of Iodized Oil in Goiter Prophylaxis", MEDICINE, vol. 80, no. 1, 1 January 2001 (2001-01-01), pages 20 - 36, XP055407131, Retrieved from the Internet <URL:http://pdfs.journals.lww.com/md-journal/2001/01000/Physiology\_and\_Pharmacology\_of\_Iodized\_Oil\_in.3.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1505475731991;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKJTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7Ih [retrieved on 20170915]

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2012172192 A1 20121220**; EP 2720687 A1 20140423; FR 2976491 A1 20121221; FR 2976491 B1 20150710

DOCDB simple family (application)  
**FR 2012000231 W 20120608**; EP 12731520 A 20120608; FR 1101814 A 20110614